Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.
Mammalian target of rapamycin (mTOR) signaling has been associated with aggressive tumor growth in many cancer models, although its role in urothelial carcinoma (UCC) has not been extensively explored. Expression of phosphorylated mTOR (P-mTOR) and a downstream target, ribosomal S6 protein (P-S6), was identified in 74% (90/121) and 55% (66/121) of muscle-invasive UCCs, respectively. P-mTOR intensity and %positive cells were associated with reduced disease-specific survival (P = 0.04, P = 0.08, respectively). Moreover, P-mTOR intensity corresponded to increased pathological stage (P < 0.01), and mTOR activity was associated with cell migration in vitro. In addition, mTOR inhibition via rapamycin administration reduced cell proliferation in UCC cell lines RT4, T24, J82, and UMUC3 in a dose-dependent manner to 6% of control levels and was significant at 1 nmol/L in J82, T24, and RT4 cells (P < 0.01, P < 0.01, P = 0.03, respectively) and at 10 nmol/L in UMUC3 cells (P = 0.03). Reduced proliferation corresponded with reduced P-S6 levels by Western blot, and effects were ablated by pretreatment of cells with mTOR-specific siRNA. No effects of rapamycin on apoptosis were identified by TUNEL labeling or PARP cleavage. Administration of rapamycin to T24-xenografted mice resulted in a 55% reduction in tumor volume (P = 0.03) and a 40% reduction in proliferation (P < 0.01) compared with vehicle-injected mice. These findings indicate that mTOR pathway activation frequently occurs in UCC and that mTOR inhibition may be a potential means to reduce UCC growth.
Hansel
Donna E
DE
Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio, USA. hanseld@ccf.org
Platt
Eric
E
Orloff
Mohammed
M
Harwalker
Jyoti
J
Sethu
Swathi
S
Hicks
Jessica L
JL
De Marzo
Angelo
A
Steinle
Roxanne E
RE
Hsi
Eric D
ED
Theodorescu
Dan
D
Ching
Christina B
CB
Eng
Charis
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor / Q000187:drug effects; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009368:Neoplasm Transplantation; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism*; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D020123:Sirolimus / Q000494:pharmacology; D015996:Survival Rate; D058570:TOR Serine-Threonine Kinases; D014183:Transplantation, Heterologous; D001749:Urinary Bladder Neoplasms / Q000378:metabolism / Q000473:pathology
D047908:Intracellular Signaling Peptides and Proteins; C546842:MTOR protein, human; C546843:mTOR protein, mouse; D017346:Protein Serine-Threonine Kinases; D038762:Ribosomal Protein S6 Kinases, 70-kDa; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus
J Biol Chem. 2007 Dec 7;282(49):35803-13
17928295
Cancer Res. 2009 Nov 1;69(21):8256-64
19843858
Br J Cancer. 1999 May;80(5-6):904-8
10360673
Oncogene. 2004 Sep 2;23(40):6788-97
15273733
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5
11504907
Nat Genet. 1997 May;16(1):64-7
9140396
Urology. 2009 Mar;73(3):665-8; discussion 668-9
19081609
Expert Rev Mol Med. 2008 Feb 04;10:e4
18241520
J Clin Oncol. 1997 Jul;15(7):2564-9
9215826
Oncol Rep. 2006 Jul;16(1):57-63
16786123
J Biol Chem. 2005 Jul 8;280(27):25485-90
15899889
J Pathol. 2001 Jul;194(3):349-57
11439368
Nat Rev Cancer. 2006 Sep;6(9):729-34
16915295
Nat Rev Cancer. 2008 Nov;8(11):851-64
18846101
J Clin Oncol. 2004 Mar 1;22(5):909-18
14990647
J Natl Cancer Inst. 2000 Jun 7;92(11):924-30
10841828
J Biol Chem. 2003 Aug 8;278(32):29655-60
12777372
Hum Mol Genet. 2008 Jul 1;17(13):2006-17
18397877
J Clin Oncol. 2005 Aug 10;23(23):5314-22
15955899
Mol Cancer Ther. 2006 Oct;5(10):2494-502
17041093
Nat Rev Cancer. 2005 Sep;5(9):713-25
16110317
Oncogene. 1997 Jun 26;14(25):3059-66
9223669
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89
16467077
Mol Carcinog. 2000 Nov;29(3):143-50
11108659
Oncogene. 2004 Jul 29;23(34):5853-7
15208673
Eur J Cancer. 2008 May;44(7):1022-9
18375114
J Cell Biol. 2007 Jul 30;178(3):437-51
17646396
Cancer Cell. 2005 Sep;8(3):179-83
16169463
Mol Cell. 2006 Apr 21;22(2):159-68
16603397
J Urol. 1987 Apr;137(4):663-7
3560318
N Engl J Med. 2007 May 31;356(22):2271-81
17538086
Cancer Res. 2008 Apr 15;68(8):2934-43
18413763
Oncogene. 1993 Apr;8(4):1083-5
8096074
Genes Dev. 2009 Mar 15;23(6):675-80
19261747
Urology. 2007 Jan;69(1 Suppl):62-79
17280909
J Cell Physiol. 2000 Mar;182(3):311-22
10653597
Expert Rev Anticancer Ther. 2008 Feb;8(2):283-92
18279068